Petros Pharmaceuticals Inc

$0.09
(as of Mar 28, 3:57 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Petros Pharmaceuticals Inc

Stock Price
$0.09
Ticker Symbol
PTPI
Exchange
NASDAQ

Industry Information for Petros Pharmaceuticals Inc

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic

Company Description for Petros Pharmaceuticals Inc

Country
USA
Full Time Employees
21

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

Fundamentals for Petros Pharmaceuticals Inc

Market Capitalization
$2,573,954
EBITDA
$-10,609,838
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-3.80
Earnings per Share Estimate Next Year
Profit Margin
-117.52%
Shares Outstanding
29,929,700
Percent Owned by Insiders
5.75%
Percent Owned by Institutions
8.68%
52-Week High
52-Week Low

Technical Indicators for Petros Pharmaceuticals Inc

50-Day Moving Average
200-Day Moving Average
RSI
43.05
0.03

Analyst Ratings for Petros Pharmaceuticals Inc

Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0

News About Petros Pharmaceuticals Inc

Jun 17, 2024, 3:08 AM EST
EXCLUSIVE: 'Prescription Erectile Dysfunction Market Could Triple If an ED Therapy Is Made Available OTC,' Petros Pharma President Says See more.
Aug 29, 2022, 11:10 AM EST
Delivers Overview of New Strategy for Leveraging AMMO’s Existing Assets and Evolving the Company into a Diversified, Growing and Profitable Ecommerce Powerhouse See more.
Jul 28, 2022, 10:27 AM EST
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Petros Pharmaceuticals, Inc. See more.
Jul 28, 2022, 9:25 AM EST
Petros Pharmaceuticals to become a privately-owned company operating independently as part of Henry Crown and Company’s healthcare platform See more.